IGC Pharma (IGC) Receivables (2011 - 2026)
IGC Pharma (IGC) posted quarterly Receivables of $694000.0 for Q1 2026, up 1941.18% year-over-year from $34000.0 in Q1 2025, and up 2.21% quarter-over-quarter from $679000.0 in Q4 2025.
IGC Pharma (IGC) Receivables (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Receivables for 16 consecutive years, with $694000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 1941.18% year-over-year to $694000.0; the TTM figure through Mar 2026 stood at $694000.0 (up 1941.18% YoY), while the FY2026 annual figure was $694000.0, down 2.8% from the prior year.
- Receivables advanced to $694000.0 in Q1 2026 per IGC's latest filing, from $679000.0 in the prior quarter.
- Across five years, Receivables topped out at $1.2 million in Q2 2023 and bottomed at -$272000.0 in Q1 2024.
- Historically, Receivables has averaged $655294.1 across 5 years, with a median of $714000.0 in 2024.
- Annual changes were most pronounced in 2024 — Receivables sank 263.86% — and 2026, when it surged 1941.18%.
- IGC Pharma's Receivables stood at $1.0 million in 2022, then rose by 3.59% to $1.0 million in 2023, then declined by 29.87% to $728000.0 in 2024, then slipped by 6.73% to $679000.0 in 2025, then increased by 2.21% to $694000.0 in 2026.
- Business Quant data shows IGC's Receivables at $694000.0 in Q1 2026, $679000.0 in Q4 2025, and $711000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | 694,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 694,000.00 |
| Dec 31, 2025 | 679,000.00 |
| Sep 30, 2025 | 711,000.00 |
| Jun 30, 2025 | 767,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | 728,000.00 |
| Sep 30, 2024 | 729,000.00 |
| Jun 30, 2024 | 714,000.00 |
| Mar 31, 2024 | -272,000.00 |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | 166,000.00 |
| Dec 31, 2022 | 1.00 Mn |
| Sep 30, 2022 | 940,000.00 |
| Jun 30, 2022 | 501,000.00 |
| Mar 31, 2022 | 449,000.00 |
| Dec 31, 2021 | 546,000.00 |
| Sep 30, 2021 | 514,000.00 |
| Jun 30, 2021 | 537,000.00 |